BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its position in shares of Iqvia Holdings Inc (NYSE:IQV) by 77.1% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 128,394 shares of the medical research company’s stock after purchasing an additional 55,897 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp owned 0.06% of Iqvia worth $12,816,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC boosted its holdings in shares of Iqvia by 19.4% during the 2nd quarter. Steward Partners Investment Advisory LLC now owns 2,933 shares of the medical research company’s stock valued at $293,000 after acquiring an additional 476 shares during the last quarter. Louisiana State Employees Retirement System boosted its holdings in shares of Iqvia by 6.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 9,500 shares of the medical research company’s stock valued at $948,000 after acquiring an additional 600 shares during the last quarter. Private Capital Group LLC boosted its holdings in shares of Iqvia by 177.0% during the 1st quarter. Private Capital Group LLC now owns 1,061 shares of the medical research company’s stock valued at $104,000 after acquiring an additional 678 shares during the last quarter. Howard Capital Management boosted its holdings in shares of Iqvia by 0.6% during the 2nd quarter. Howard Capital Management now owns 125,625 shares of the medical research company’s stock valued at $12,540,000 after acquiring an additional 710 shares during the last quarter. Finally, Suntrust Banks Inc. boosted its holdings in shares of Iqvia by 7.3% during the 1st quarter. Suntrust Banks Inc. now owns 10,496 shares of the medical research company’s stock valued at $1,029,000 after acquiring an additional 716 shares during the last quarter. Institutional investors and hedge funds own 91.98% of the company’s stock.

IQV opened at $126.56 on Wednesday. The company has a current ratio of 1.13, a quick ratio of 1.13 and a debt-to-equity ratio of 1.40. The company has a market capitalization of $25.41 billion, a P/E ratio of 29.00, a price-to-earnings-growth ratio of 1.80 and a beta of 0.72. Iqvia Holdings Inc has a 12-month low of $91.57 and a 12-month high of $126.95.

Iqvia (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 24th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.15. The company had revenue of $2.57 billion for the quarter, compared to the consensus estimate of $2.50 billion. Iqvia had a net margin of 12.68% and a return on equity of 13.51%. The company’s revenue was up 9.0% on a year-over-year basis. equities research analysts predict that Iqvia Holdings Inc will post 5.13 earnings per share for the current year.

In other Iqvia news, Director Ronald A. Rittenmeyer sold 7,680 shares of Iqvia stock in a transaction that occurred on Thursday, July 26th. The shares were sold at an average price of $122.41, for a total transaction of $940,108.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Cpp Investment Board Private H sold 9,291,036 shares of Iqvia stock in a transaction that occurred on Friday, June 15th. The shares were sold at an average price of $103.00, for a total transaction of $956,976,708.00. The disclosure for this sale can be found here. In the last three months, insiders sold 11,201,623 shares of company stock worth $1,160,990,595. 6.00% of the stock is currently owned by insiders.

A number of analysts have recently issued reports on the stock. Barclays reaffirmed an “overweight” rating and set a $130.00 price target (up previously from $120.00) on shares of Iqvia in a report on Wednesday, July 25th. Stifel Nicolaus raised their price target on shares of Iqvia from $128.00 to $150.00 and gave the company a “buy” rating in a report on Wednesday, July 25th. ValuEngine raised shares of Iqvia from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Raymond James raised shares of Iqvia from an “outperform” rating to a “strong-buy” rating in a report on Tuesday, July 3rd. Finally, Mizuho set a $120.00 price target on shares of Iqvia and gave the company a “hold” rating in a report on Monday, August 6th. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. Iqvia has an average rating of “Buy” and a consensus target price of $125.78.

Iqvia Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Recommended Story: Fundamental Analysis and Individual Investors

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.